Table 1.

The characteristics of eight ferumoxytol studies at our institution.

IRB#	Objective	n	Pathologies	Fe injections and total doses	ref
8097	ferumoxytol MRI enhancement time course in brain tumors	13	Primary BT: 12 Metastasis: 1	1.: 1mg/kg 2.: 3mg/kg Total: 4mg/kg	8, 9
2753	vascular cerebral imaging with ferumoxytol throughout standard GBM radio/chemotherapy	12	GBM: 12	2 mg/kg Total: 2mg/kg	5, 33, 35–37
2864	permeability and perfusion MRI in brain tumors using ferumoxytol and gadolinium in 3T and 7T magnets.	20	High grade BT: 17 Low grade BT: 2 Meningioma: 1	1.: 1mg/kg 2.: 3mg/kg Total: 4 mg/kg	33, 35– 37
1562*	ferumoxytol vs. gadolinium imaging in various CNS pathologies	156	Meningioma: 12 Primary BT: 74 Metastasis: 20 Vascular: 18 Demyelination: 10 Spine: 4; Other: 18	1.: 75mg 2.: 150mg 3.: 285mg Total 510mg	5, 33, 35–41
3678	changes in brain tumor vascularity after antiangiogenic therapy versus steroid therapy	5	GBM: 5	2 mg/kg Total: 2mg/kg	33, 42
5405	vascular properties of pediatric brain tumors using ferumoxytol	12	High grade: 8 Low grade: 4	1.: 1mg/kg 2.: 1–3mg/kg Total 2–4 mg/kg	43
813	ferumoxytol and gadolinium imaging of brain tumors in a single imaging session	123	Primary BT: 105 CNS lymphoma: 5 Metastasis: 13	1.: 1mg/kg 2.: 3mg/kg Total: 4 mg/kg	37, 38, 41
9846*	steady state blood volume imaging throughout glioblastoma treatment	9	GBM: 7 Other: 2	1.: 1mg/kg 2.: 2mg/kg 3.: 4mg/kg** Total: 7 mg/kg**

^*Ongoing trials. IRB: Institutional Review Board n: number of subjects (the same subject may have participated in more than one protocol. BT: brain tumor GBM: glioblastoma.

^**total dose 7mg/kg, but not exceeding 510mg total.